Search Results - Lecia V. Sequist

Refine Results
  1. 1
    <i>AJRCCM</i>: 100-Y<scp>ear</scp> A<scp>nniversary</scp>.The Shifting Landscape for Lung Cancer: Past, Present, and Future

    <i>AJRCCM</i>: 100-Y<scp>ear</scp> A<scp>nniversary</scp>.The Shifting Landscape for Lung Cancer: Past, Present, and Future by Anil Vachani, Lecia V. Sequist, Avrum Spira

    Published 2017
    Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Genetic Changes in Squamous Cell Lung Cancer: A Review

    Genetic Changes in Squamous Cell Lung Cancer: A Review by Rebecca S. Heist, Lecia V. Sequist, Jeffrey A. Engelman

    Published 2012
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    Targeting<i>EGFR</i>Exon 20 Insertions in Non–Small Cell Lung Cancer: Recent Advances and Clinical Updates

    Targeting<i>EGFR</i>Exon 20 Insertions in Non–Small Cell Lung Cancer: Recent Advances and Clinical Updates by Catherine B. Meador, Lecia V. Sequist, Zofia Piotrowska

    Published 2021
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    Update to Rociletinib Data with the RECIST Confirmed Response Rate

    Update to Rociletinib Data with the RECIST Confirmed Response Rate by Lecia V. Sequist, Jean‐Charles Soria, D. Ross Camidge

    Published 2016
    Get full text Get full text
    Carta
    Save to List
    Saved in:
  5. 5
    Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management

    Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management by Alissa J. Cooper, Lecia V. Sequist, W. Marston Linehan

    Published 2022
    Get full text
    Revisão
    Save to List
    Saved in:
  6. 6
    Response to Osimertinib in an EGFR Exon 20 Insertion-Positive Lung Adenocarcinoma

    Response to Osimertinib in an EGFR Exon 20 Insertion-Positive Lung Adenocarcinoma by Zofia Piotrowska, Florian J. Fintelmann, Lecia V. Sequist, Balkrishna Jahagirdar

    Published 2018
    Get full text Get full text
    Carta
    Save to List
    Saved in:
  7. 7
    Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin

    Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin by Matthew G. Oser, Matthew J. Niederst, Lecia V. Sequist, Jeffrey A. Engelman

    Published 2015
    Get full text
    Revisão
    Save to List
    Saved in:
  8. 8
    The CTC-Chip: An Exciting New Tool to Detect Circulating Tumor Cells in Lung Cancer Patients

    The CTC-Chip: An Exciting New Tool to Detect Circulating Tumor Cells in Lung Cancer Patients by Lecia V. Sequist, Sunitha Nagrath, Mehmet Toner, Daniel A. Haber, Thomas J. Lynch

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Can CT radiomic analysis in NSCLC predict histology and EGFR mutation status?

    Can CT radiomic analysis in NSCLC predict histology and EGFR mutation status? by Subba R. Digumarthy, Atul Padole, Roberto Lo Gullo, Lecia V. Sequist, Mannudeep K. Kalra

    Published 2019
    Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer

    Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer by Meghan Campo, H. Al-Halabi, Melin J. Khandekar, Alice T. Shaw, Lecia V. Sequist, Henning Willers

    Published 2016
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  11. 11
    Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Therapy

    Pattern of Failure Analysis in Metastatic EGFR-Mutant Lung Cancer Treated with Tyrosine Kinase Inhibitors to Identify Candidates for Consolidation Stereotactic Body Radiation Thera... by H. Al-Halabi, Karl Sayegh, Subba R. Digamurthy, Andrzej Niemierko, Zofia Piotrowska, Henning Willers, Lecia V. Sequist

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib

    Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib by Lecia V. Sequist, Zofia Piotrowska, Matthew J. Niederst, Rebecca S. Heist, Subba R. Digumarthy, Alice T. Shaw, Jeffrey A. Engelman

    Published 2015
    Get full text Get full text
    Carta
    Save to List
    Saved in:
  13. 13
    Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

    Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors by Sarah B. Goldberg, Geoffrey R. Oxnard, Subba R. Digumarthy, Alona Muzikansky, David M. Jackman, Inga T. Lennes, Lecia V. Sequist

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Predicting malignant potential of subsolid nodules: can radiomics preempt longitudinal follow up CT?

    Predicting malignant potential of subsolid nodules: can radiomics preempt longitudinal follow up CT? by Subba R. Digumarthy, Atul Padole, Shivam Rastogi, Melissa C. Price, Meghan J. Mooradian, Lecia V. Sequist, Mannudeep K. Kalra

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    FGFR1 Amplification in Squamous Cell Carcinoma of The Lung

    FGFR1 Amplification in Squamous Cell Carcinoma of The Lung by Rebecca S. Heist, Mari Mino‐Kenudson, Lecia V. Sequist, Swathi Tammireddy, L Morrissey, David C. Christiani, Jeffrey A. Engelman, A. John Iafrate

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Predicting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer

    Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in Predicting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer by Raymond H. Mak, Subba R. Digumarthy, Alona Muzikansky, Jeffrey A. Engelman, Jo-Anne O. Shepard, Noah C. Choi, Lecia V. Sequist

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Delay of treatment change after objective progression on first‐line erlotinib in epidermal growth factor receptor‐mutant lung cancer

    Delay of treatment change after objective progression on first‐line erlotinib in epidermal growth factor receptor‐mutant lung cancer by Peter Lo, Suzanne E. Dahlberg, Mizuki Nishino, Bruce E. Johnson, Lecia V. Sequist, David M. Jackman, Pasi A. Jänne, Geoffrey R. Oxnard

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies

    The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies by Matthew J. Niederst, Haichuan Hu, Hillary E. Mulvey, Elizabeth L. Lockerman, Angel R. Garcia, Zofia Piotrowska, Lecia V. Sequist, Jeffrey A. Engelman

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer

    EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer by April F. Eichler, Kristopher T. Kahle, D. L. Wang, Victoria A. Joshi, Henning Willers, J. A. Engelman, Thomas J. Lynch, Lecia V. Sequist

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Outcomes After Combined Modality Therapy for<i>EGFR</i>-Mutant and Wild-Type Locally Advanced NSCLC

    Outcomes After Combined Modality Therapy for<i>EGFR</i>-Mutant and Wild-Type Locally Advanced NSCLC by Raymond H. Mak, Elizabeth Doran, Alona Muzikansky, Josephine Kang, Joel W. Neal, Noah C. Choi, Henning Willers, David M. Jackman, Lecia V. Sequist

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: